The KLIFO history

Alejandra Mørk had seen this pattern again and again as a senior pharma executive.

“What was missing was someone who could see the full horizon.”

In 2008, she acquired KLIFO—not to take it over, but to reinvent it. The vision was clear: build a consulting house for pharmaceutical development, led by senior experts who could bridge strategy and execution.

“We’re not an army of junior consultants here to fill hours.
We’re the people who step in when it really matters.”

The approach worked. KLIFO grew steadily, not through sales, but through reputation. Clients came because they felt the difference—getting the right guidance at the right time, with a clear focus on approval.

As demand grew, so did KLIFO. New departments were added, and the company expanded into Germany, Sweden, and the Netherlands. In 2021, Gilde Healthcare invested—not to change KLIFO, but to scale what made it unique.

Today, KLIFO stands as a North European consultancy powerhouse, still driven by the same DNA:
➡️ Experts who understand the full spectrum of drug development
➡️ A true advisor and operator in one

A new management team has been established, while Alejandra Mørk continues adding value in her position as Strategic Development Advisor.

Blue button “Meet the management team” (and link to that subpage)